Medicine & Life Sciences

1. Hodgkin Disease 100%
2. Non-Hodgkin's Lymphoma 99%
3. Waldenstrom Macroglobulinemia 94%
4. Lymphoma 78%
5. Lymphoma, Large B-Cell, Diffuse 74%
6. Follicular Lymphoma 62%
7. Survival 51%
8. B-Cell Lymphoma 48%
9. Rituximab 46%
10. Progression-Free Survival 44%
11. Brentuximab Vedotin 43%
12. B-Lymphocytes 35%
13. T-Lymphocytes 34%
14. Stem Cell Transplantation 32%
15. Therapeutics 29%
16. Neoplasms 28%
17. Nivolumab 25%
18. Drug Therapy 25%
19. Tumor Microenvironment 23%
20. Transplants 22%
21. Peripheral T-Cell Lymphoma 21%
22. T-Cell Lymphoma 21%
23. Anaplastic Large-Cell Lymphoma 21%
24. Peripheral Blood Stem Cell Transplantation 19%
25. Lymphocyte Count 19%
26. Confidence Intervals 18%
27. Immunoglobulin M 18%
28. Lymphocytes 18%
29. Hematopoietic Stem Cell Transplantation 18%
30. Multiple Myeloma 17%
31. Chimeric Antigen Receptors 16%
32. Hematologic Neoplasms 16%
33. Monocytes 16%
34. PCI 32765 16%
35. Mantle-Cell Lymphoma 15%
36. Stem Cells 15%
37. Lymphoproliferative Disorders 14%
38. Recurrence 14%
39. Cyclophosphamide 14%
40. Immunotherapy 13%
41. Lenalidomide 13%
42. Clinical Trials 13%
43. Autografts 12%
44. Bone Marrow 12%
45. B-Cell Chronic Lymphocytic Leukemia 12%
46. Immunoglobulin Light-chain Amyloidosis 11%
47. Cytokines 11%
48. Doxorubicin 11%
49. Ligands 10%
50. Radiotherapy 10%